Avid Bioservices (NASDAQ:CDMO – Get Free Report) and TetraLogic Pharmaceuticals (OTCMKTS:TLOG – Get Free Report) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, institutional ownership, dividends, risk, valuation and profitability. Insider & Institutional Ownership 0.0% of TetraLogic Pharmaceuticals […]
Pfizer (NYSE:PFE – Get Free Report) and TetraLogic Pharmaceuticals (OTCMKTS:TLOG – Get Free Report) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, analyst recommendations, institutional ownership, risk and valuation. Profitability This table compares Pfizer and TetraLogic Pharmaceuticals’ net […]
/PRNewswire/ April – June Financial summary for the quarter Net turnover amounted to SEK 0.9 (4.0) million. The loss before interest, tax, depreciation and.
/PRNewswire/ Medivir AB (Nasdaq Stockholm: MVIR) announced today that Medivir AB ("Medivir" or "the Company") together with the originators of remetinostat,.
Financing secured to bring the MIV-818 study into the next phase
January – March
Net turnover amounted to SEK 9.9 (7.3) million.
The loss before interest, tax, depreciation and amortization (EBITDA) amounted to SEK -7.2 (-20.7) million. Basic and diluted earnings per share amounted to SEK -0.18 (-0.96) and SEK -0.18 (-0.96) respectively.
Cash flow from operating activities amounted to SEK -1.5 (-16.6) million.
Liquid assets and short-term investments at the end of the period amounted to SEK 269.3 (116.6) million.
Significant events during the quarter
In January the company signed an exclusive license agreement with IGM Biosciences, Inc. for birinapant. Medivir received a payment of USD 1 million after signing, which is to be followed by an additional USD 1.5 million when IGM includes birinapant in phase I clinical trials. In addition, the agreement entitles Medivir to milestone payments and royalties.